Licensing deal frees up Europharma for R&D
operations in order to focus on R&D with the signing of a new
licensing and distribution agreement for its existing IP and
products with Blue Spring Wellness, reports Jess Halliday.
The deal, announced yesterday, gives Blue Spring the right to use EuroPharma's trademarks and to sell its portfolio of products, including supplements for weight loss and fat blocking, joint health, immunity, energy, stress, cognitive function, men's and women's health and cognitive function.
This is the second such agreement that the Wisconsin company has entered into in recent months. In March it announced the inking of a deal with Enzymatic Therapy for its Renouvelle topical anti-aging skin care and SneezeEze allergy relief products.
At the center of its new product program, which involves sourcing and importing unique products primarily from Europe and Asia, is a collaborative effort to bring a new immune modulator to market. According to the company, which calls it "the next generation in joint health", the product has been clinically studied in subjects with osteoarthritis and was seen to perform even better than glucosamine.
EuroPharma has obtained the exclusive US license to this patented product and further details are expected to be available in the near future.
Also impending is an announcement about licensing partnerships for a patent-pending carb blocker product, a new, patented fat inhibiting molecule that is said to block absorption of 25 grams of fat per day, and a new anti-viral product.
"We see an enormous opportunity to bring new life and energy to the new products arena - products that are based on science and meet the guidelines of the FDA and FTC," said EuroPharma founder and president Terry Lemerond.
"By partnering on these and other products with highly reputable companies we can significantly impact the growth of the natural products industry."
